Corps AN, Hesketh TR, Metcalfe JC Limitations on the use of phenothiazines and local anaesthetics as indicators of calmodulin function in intact cells. FEBS Lett. 1982 Feb 22;138(2):280-4. doi: 10.1016/0014-5793(82)80461-4. No abstract available.
Hamburg NM, Benjamin EJ Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009 Jan;19(1):6-11. doi: 10.1016/j.tcm.2009.03.001.
Hansson GK Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. doi: 10.1056/NEJMra043430. No abstract available.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19.
Niel E, Scherrmann JM Colchicine today. Joint Bone Spine. 2006 Dec;73(6):672-8. doi: 10.1016/j.jbspin.2006.03.006. Epub 2006 Sep 1.
Pope RM, Tschopp J The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007 Oct;56(10):3183-8. doi: 10.1002/art.22938. No abstract available.
von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A [Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate]. Hamostaseologie. 2007 Aug;27(3):155-60; quiz 161-2. doi: 10.1007/978-3-540-36715-4_49. German.
Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
